Serogroup B Meningococcal Vaccine Found Effective
The Lancet Infectious Diseases reported on September 7, 2022, that researchers found good immunogenicity, short-lived antibody persistence, and acceptable reactogenicity profile of meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp, Trumenba®).
Pfizer Inc.'s Trumenba contains two factor-H-binding proteins (FHbp) against serogroup B meningococcal disease in children aged 1–9 years.
The data were collected during Pfizer-funded phase 2 studies in Australia and Europe, with 396 toddlers (age 12–23 months) and 400 older children (aged 2–9 years) randomly assigned to receive either MenB-FHbp (60 μg [toddler study only] or 120 μg) or a control vaccine (hepatitis A vaccine and saline) in a three-dose primary schedule (0, 2, and 6 months).
Trumenba was found well tolerated and induced protective immune responses in a high proportion of participants.
These findings support a favorable MenB-FHbp immunogenicity and reactogenicity profile in young children, a population at increased risk of adverse invasive meningococcal disease outcomes.
The strong immune response to a booster dose observed in the study can be interpreted as showing immune memory, stated these researchers.